Drug intelligence / Profile preview

Isoformononetin

Development stage
Preclinical
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Isoformononetin is a naturally occurring methoxyisoflavone, structurally related to daidzein, and classified as a hydroxyisoflavone and member of the 7-methoxyisoflavones. It is found in plants such as Glycine max (soybean) and Pueraria montana var. lobata (kudzu). Isoformononetin exhibits several biological activities, including acting as an antioxidant, anti-inflammatory agent, bone density conservation agent, apoptosis inhibitor, and immunoprotective compound. Mechanistically, it has been shown to inhibit neuroinflammation by reducing reactive oxygen species (ROS) generation and suppressing activation of the NLR family pyrin domain containing 3 (NLRP3)/ASC/IL‑1 axis in preclinical models. It also modulates apoptotic gene expression (Bax/Bcl2), inhibits Th17 and B-cell differentiation, and demonstrates neuroprotective effects against chemically induced neuronal injury in animal studies[1][3][5].

Other names
3-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one4'-hydroxy-7-methoxyisoflavoneISOFORMONENTIN
02

Targets

IL1B (Interleukin-1 beta)RELA (Nuclear Factor Kappa B Subunit p65)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on Isoformononetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isoformononetin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call